High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission  by Nademanee, Auayporn et al.
INTRODUCTION
A p p roximately 70–90% of patients with advanced-stage
H o d g k i n ’s disease (HD) can achieve a complete re m i s s i o n
High-dose chemo/radiotherapy and autologous bone
marrow or stem cell transplantation for poor-risk
advanced-stage Hodgkin’s disease during first partial or
complete remission
A u a y p o rn Nademanee,1 A rt u ro Molina,1 H e n ry Fung,1 Anthony Stein,1 Pablo Parker,1 Ina Planas,1 M a rg a re t
R. O’Donnell,1 David S. Snyder,1 Ashwin Kashyap,1 R i c a rdo Spielberg e r,1 Ravi Bhatia,1 Amrita Krishnan,1
I rena Sniecinski,2 Nayana Vo r a ,3 Marilyn Slovak,4 A n d rew Dagis,5 Joyce C. Niland,5 Stephen J. Form a n1
1D e p a rtment of Hematology and Bone Marrow Transplantation, 2D e p a rtment of Transfusion Medicine, 3D e p a rtment of
Radiation Oncology, 4Clinical Pathology, and 5Biostatistics, City of Hope National Medical Center, Duarte, Californ i a
O ffprint requests: Auayporn Nademanee, MD, Department of Hematology and Bone Marrow Transplantation, City of
Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010
(Received 9 Febru a ry 1999; accepted 24 June 1999)
ABSTRACT
Complete remission rates of 70–90% can be achieved following combination chemotherapy for patients with
advanced-stage Hodgkin’s disease (HD). Patients who present with unfavorable poor prognostic factors, however,
have a 5-year disease-free survival of only 40–50%. In an attempt to improve the prognosis of 20 patients with poor-
risk advanced-stage HD, we evaluated the role of early high-dose therapy (HDT) and autologous bone marro w / s t e m
cell transplantation (ASCT) during the first complete or partial remission (CR/PR). Patients were eligible for ASCT
if they either achieved a PR (defined as .50% re g ression) (six patients), or achieved a CR (14 patients) but had pre-
sented with three or more of the following unfavorable features: stage IV disease with bone marrow involvement or
$2 extranodal sites of involvement; bulky mass .10 cm or bulky mediastinal mass .1/3 of mediastinal/thoracic ratio;
B symptoms; and elevated serum lactate dehydrogenase (LDH) level. The study included 11 men (55%) and 
9 women (45%). The median age was 37 years (range 20–57). Seventeen patients (85%) had stage IV disease; 14
(70%) had B symptoms; 13 (65%) had bulky mass .10 cm; 14 (70%) had $2 extra nodal sites involvement; and eight
patients (40%) had elevated LDH levels. All patients were treated with standard four or 7–8 drug combination
chemotherapy regimens until they achieved maximal response prior to ASCT with a median of six cycles (range
4–11). Six patients also received involved field radiotherapy to residual bulky mass .5 cm or bony lesions before
A S C T. The median time from diagnosis to ASCT was 8.6 months (range 5.5–18.9). Preparative regimens consisted of
fractionated total body irradiation (FTBI) 1200 cGy in combination with etoposide 60 mg/kg and cyclophosphamide
100 mg/kg in all patients except one who had borderline pulmonary function and received lomustine 15 mg/kg
instead of FTBI. All patients engrafted and there was no transplant-related mort a l i t y. One patient developed conges-
tive cardiomyopathy at 4 years post-ASCT. All patients remain alive and in remission at a median follow-up of 42.8
months (range, 13.2–149.2). These pre l i m i n a ry results suggest that HDT and ASCT can be perf o rmed safely during
first CR/PR in selected patients with advanced-stage HD who have an unfavorable prognosis. Further randomized
studies comparing HDT and ASCT during first CR with conventional chemotherapy and ASCT at relapse in poor-
risk advanced-stage HD should be conducted. The prognostic factors and risk groups described recently by an inter-
national prognostic study can be used to identify high-risk patients who may be candidates for more intensive therap y.
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after treatment with combination chemotherapy with or
without radiation therapy [1–3]. Despite the high initial
complete remission (CR) rate, 20–30% of the complete
responders eventually relapse; there f o re the overall initial
c u re rate for advanced-stage HD treated with conventional
a p p roaches has been re p o rted to be approximately 40–70%.
Several prognostic models have been re p o rted and pro p o s e d
to identify patients at high risk for relapse who may benefit
f rom a more intensive initial treatment plan [4–7]. D i ff e re n t
a p p roaches have also been utilized to prevent relapse and
i m p rove disease-free survival for advanced-stage HD, includ-
ing consolidative radiation therapy [8,9], more intensive
combination chemotherapy regimens with or without radio-
therapy [10,11], and early consolidation therapy with high-
dose therapy (HDT) and autologous bone marrow/stem cell
transplantation (ASCT) during first CR [12].
Treatment with HDT and autologous bone marro w
transplantation (ABMT) during first CR in high-risk HD
patients was first re p o rted by Carella et al. [12]. In that study,
stage IV HD patients with at least two diff e rent sites of extra-
lymphatic involvement, bulky mediastinal disease, B symp-
toms, and elevated serum lactate dehydrogenase (LDH) level
w e re treated with mechlorethamine, vincristine, pro c a r-
bazine, and prednisone (MOPP) alternating with doxoru b i c i n
(adriamycin), bleomycin, vinblastine, and dacarbazine
(ABVD) until achieving a CR. ABMT was off e red during fir s t
CR. Fifteen patients underwent ABMT and 24 refused. Thir-
teen of the 15 patients (86.6%) in the ABMT group were
alive and in remission at a median follow-up of 36 months
c o m p a red with eight of 24 (33%) in the non-ABMT gro u p .
These results suggested the possibility that HDT and ABMT
during first CR can improve the prognosis and likelihood of
c u re for patients with advanced-stage and poor-risk HD.
Since then, several groups have re p o rted similar experiences
with ASCT for poor-risk HD patients in first CR/PR [13–17].
We conducted a study to evaluate the role of HDT and
ASCT during first CR/PR in advanced-stage and poor-risk
HD patients. The same poor prognostic factors described
by Carella et al. [12] were used to select candidates for trans-
plant in our study. Because radiotherapy is very effective for
HD, a total body irradiation (TBI)-based high-dose regimen
was used whenever possible to provide additional local con-
t rol. We re p o rt herein the results in 20 patients with
advanced-stage and poor-risk HD who underwent HDT
and ABMT/ASCT during first CR/PR.
PATIENTS AND METHODS
Patient population
Between March 1987 and September 1997, 195 p a t i e n t s
with HD underwent HDT and ABMT or ASCT at City
of Hope National Medical Center in Duarte, CA. Tw e n t y
of these patients received transplants during first CR/PR.
The following poor prognostic factors were used to select
candidates for ASCT during first CR: stage IV disease
with bone marrow involvement or with involvement of
m o re than one extra nodal site; bulky mediastinal mass
.1/3 of mediastinal/thoracic ratio or bulky mass .10 cm;
B symptoms; and elevated LDH level. Patients with thre e
or more of these poor prognostic factors were eligible for
ASCT during first CR. Patients with any of the poor
p rognostic factors who had achieved only a PR, or
re q u i red $2 combination chemotherapy regimens to
achieve a CR, were also eligible to proceed with ASCT.
Additional criteria for entry included: age between 15 and
60 years; normal renal, hepatic, pulmonary, and card i a c
function; Karnofsky score .80%; and negative human
immunodeficiency virus (HIV) sero l o g y. All patients were
i n f o rmed of the investigative nature of this study and
i n f o rmed consent was obtained from each patient in
a c c o rdance with institutional guidelines.
All patients were treated with a standard four- or
7–8–drug combination chemotherapy regimen until achiev-
ing maximum response or remission. Some patients were
referred for transplant evaluation after having received some
if not most of the initial induction chemotherapy given by
community hematologists and medical oncologists. All
patients were presented at the lymphoma conference, at
which time clinical features and imaging studies were
reviewed, and treatment plans were discussed and form u l a ted.
If candidacy for transplant was verified at the completion of
induction chemotherapy, patients went on to bone marrow
harvest or peripheral blood stem cell collection.
Patient characteristics
The clinical characteristics of these 20 patients at the
time of diagnosis are summarized in Table 1, and their risk
Ta b le 1. Patient characteristics for 20 patients undergoing ASCT during
first CR/PR
Sex, M/F 11/9
Age, median (range) 37 (20–57)
Stage at Dx IV 17 (85%)
III 2 (10%)
IIE 1 (5%)
B symptom 14 (70%)
Bulky mass 17 (85%)
Bulky mediastinal mass 8 (40%)
$2 extranodal sites 14 (70%)
Anemia (HB , normal) 13 (65%)
Elevated LDH 8 (40%)
Albumin ,4 gm/dl 15 (75%)
Bone marrow involvement 4 (20%)
Prior chemotherapy
First-line ABVD 8 
(40%)
MOPP/ABV 5 (25%)




Second-line ABVD 2, 
MOPP 2
ESHAP 1
Median no. of cycles (range) 6 (4–11)
Median time from Dx to ASCT 9.5 (5.9–18.9) mo
ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ASCT, autolo-
gous stem cell transplant; CR, complete remission; Dx, diagnosis; ESHAP,
etoposide, methylprednisolone, cytarabine, and cisplatin; LDH, lactate dehy-
drogenase; MOPP, mechlorethamine, vincristine, procarbazine, and pred-
nisone; MOPP/ABV, MOPP plus doxorubicin, bleomycin, and vinblastine;
PR, partial remission; Stanford V, doxorubicin, vinblastine, mechlorethamine,
vincristine, bleomycin, etoposide, and prednisone.
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factors are shown in Table 2. There were 11 men (55%) and
nine women (45%) with a median age of 37 years (range 20–57).
Their histologies were nodular sclerosis in 16 patients
(80%) and mixed cellularity in four patients (20%). Their
stages at diagnoses were stage IV in 17 patients (85%), III in
two patients (10%) and IIE in one patient (5%). Fourt e e n
patients (70%) had B symptoms; 17 patients (85%) had
bulky mass, 13 of which were more than 10 cm in greatest
diameter; and nine (45%) had extensive splenic involve-
ment. All patients except two had extranodal involvement
i n c l u ding 14 (70%) with $2 extranodal sites. Serum LDH
was elevated in eight patients (40%); 13 (65%) had anemia,
(seven with hemoglobin ,10.5 gm/dL), three (15%) had
white cell counts $1 5 , 0 0 0 /mL, six (37%) had lymphocyte
counts of #8%, and 15 (75%) had serum albumin ,4.0 g m / d L .
When Care l l a ’s prognostic criteria were applied to 17
patients with stage IV disease, six patients had all four fac-
tors, seven patients had three factors, three patients had two
factors, and one patient had one factor. Prior chemotherapy
regimens are listed in Table 1. The median number of cycles
given was six (range, 4–11). Three patients were tre a t e d
with the Stanford V regimen, completing 12 weeks of treat-
ment as per protocol. Five patients re q u i red two diff e re n t
combination chemotherapy regimens to achieve a first
CR/PR; of these, two patients had biopsy-proven persistent
disease before changing regimens, and the other three had
persistent bulky mass with positive gallium scan. At the time
of transplant, 14 patients were in first CR and six were in
first PR, including four patients with residual mass and posi-
tive gallium scan, one patient with biopsy-proven persistent
disease, and one with persistent positive bone scan. Six
patients (4CRs, 2PRs) received involved radiotherapy (2000
cGy) to sites of re s i dual bulky disease including mediastinal
( t h ree patients), bone (two patients), and para-aortic (one
patient) fields, given more than 2 weeks prior to initiation of
high-dose regimen. The median time from diagnosis to
ASCT was 8.6 months (range 5.4–18.9).
P re p a r a t i v e re g i m e n
Since all patients at presentation had advanced-stage
d i sease and most had bulky diseases both above and below
the diaphragm, a TBI-based preparative regimen was
planned for all patients except one. The regimen included
fractionated TBI 1200 cGy at 120 cGy per fraction with
50% transmission lung blocks from day –8 to –5 in combi-
nation with etoposide 60 mg/kg on day –4 and cyclophos-
phamide 100 mg/kg on day –2. One patient with low diff usion
capacity received lomustine (CCNU) 15 mg/kg orally on
day –6 instead of TBI. Six patients with residual masses
.5 cm in greatest diameter, or with residual bony abnor-
malities, were considered for treatment with involved-fie l d
radiation (2000 cGy) given over a 10-day time period fol-
lowed by a week’s rest before proceeding to TBI.
A u t o l o gous marrow harvest, stem cell collection,
c r yo p re s e r vation, and r e i n f u s i o n
After completion of induction chemotherapy, all patients
u n d e rwent bilateral iliac crest bone marrow biopsies that
showed no microscopic evidence of marrow involvement by
HD at the time of bone marrow harvesting or stem cell collec-
tion. Patients with prior bone marrow involvement were tre a te d
until their bone marrow was free of HD before proceeding to
A S C T. Cytogenetic studies perf o rmed on bone marrow or
peripheral blood were also normal in all patients. Patients with
prior bone marrow involvement at the time of diagnosis
u n d e rwent reinfusion of peripheral blood stem cells (PBSCs)
collected via leukapheresis pro c e d u res as previously described
by Kessinger et al. [18]. Beginning in 1992, PBSCs were used
instead of bone marrow in our patients, even in those without
m a rrow involvement. PBSCs were collected after mobilization
Table 2. Patient characteristics and risk factors
Age/ Hgb WBC % Alb Bulky Extranodal Indication for 
Case no. sex Stage Gm/dl /µL lymph LDH gm/dl mass sites ASCT
1 34/F IVB 10.4 9900 4% Nl 3.7 No Bone PR
2 37/M IIBE NA NA NA NA 3.2 Yes, 10 cm Lung $2 regimens
3 50/F IIIAS ext 10.7 15,700 4% ↑ 3.7 Yes No PR/ $2 regimens
4 44/M IVA 12.8 6700 12% nl 4.5 Yes, 19 cm Lung, liver Poor risk & $2 regimens
5 38/F IVB 8.2 9400 12% nl 3.8 Yes, 8 cm Lung, BM $2 regimens
6 37/M IVA 15.1 12,500 9% ↑ 4.4 Yes, 18 cm Pleura Poor risk
7 43/M IVB 10.8 5400 8% ↑ 3.7 Yes, 15 cm BM Poor risk
8 37/M IVA 13.9 15,100 5% nl 4.7 No Bone Poor risk
9 40/F IVB 9.4 10,400 10% nl 3.9 Yes Liver, lung Poor risk
10 25/M IVB 14.0 9400 NA nl 3.7 Yes, 10 cm Lung PR
11 27/F IVB 11.0 12,500 22% ↑ 3.8 Yes, 10 cm Lung, liver, Poor risk
12 30/M IVB 9.7 11,000 7% nl 3.0 Yes, 12 cm Lung, liver Poor risk
13 20/M IVB 9.7 5500 NA ↑ NA Yes, 12 cm Bone, liver PR
14 33/F IVB 13.1 13,500 18% ↑ 2.9 Yes, 13 cm Lung, pleura Poor risk
15 28/M IVB 9.7 4200 13% nl 2.4 Yes Liver, lung, bone Poor risk
16 44/F IVA 10.1 12,200 13% nl 3.8 Yes, 18 cm Bone, liver, BM PR
17 57/M IIIA 13.6 9100 15% nl NA Yes, 15 cm No PR/ $2 regimens
18 43/F IVB 12.0 11,600 NA ↑ 3.7 Yes, 15 cm Pleura, lung Poor risk
19 20/M IVB 12.8 15,300 20% nl 3.3 No Bone, BM Poor risk
20 28/F IVB 13.9 7300 1% ↑ 3.1 Yes, .15 cm Pleura, lung Poor risk
Alb, albumin; ASCT, autologous stem cell transplant; BM, bone marrow; Hgb, hemoglobin; LDH, lactate dehydrogenase; lymph, lymphocyte count;  NA, not
available; nl, normal; PR, partial remission; WBC, white blood cell; ↑, elevated.
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with filgrastim (G-CSF) alone, or with G-CSF given after
the last cycle of conventional chemotherapy, or following
h i g h -dose etoposide 2 gm/m2 (two patients) or high-dose
cyclophosphamide 1.5 gm/m2 (two patients) and G-CSF. The
m a rrow and PBSCs were reinfused 48 hours after completion
of cyclophosphamide (day 0). G-CSF was given ro u t i n e l y
post-PBSC reinfusion once it became commercially available.
S u p p o rtive care was provided as previously described [19].
Study e v a l u a t i o n
B e f o re transplant, all patients were evaluated by physical
examination; complete blood count; blood chemistry pro fil e ;
hepatitis panel; HIV antibody test; chest X-ray; chest, abdomin a l
and pelvic computerized tomography (CT) scan; and bone
m a rrow aspiration and biopsy. Gallium scans were also per-
f o rmed ro u t i n e l y, particularly for patients with residual mass,
to determine gallium avidity. Bone scans were perf o rmed only
in those with a prior history of bone involvement. Follow-up
restaging with CT scans and gallium scan were perf o rmed at
30–60 days post-ASCT to determine the response. There a f t e r,
CT scans were perf o rmed every 6 months during the first
2 years after transplant or more often as clinically indicated,
and then yearly through 5 years after ASCT.
Response definitions
Complete remission (CR) was defined as complete re s o l u-
tion of all disease-related symptoms and normalization of all
initial physical examination, laboratory, and imaging abnor-
malities, including X-rays and CT scan, or a .75% re d u c t i o n
of lymph node masses lasting at least 3 months. Patients with
residual masses re q u i red a negative gallium scan to qualify for
CR status. Patients were considered to be in PR if they had
resolution of disease-related symptoms and a .50% re d u c t i o n
in the diameter of all measurable lesions for at least 3 months.
Induction failure was defined as ,50% reduction in measur-
able disease, or reappearance of disease-related symptoms,
detection of disease in a new site, or measurable growth of dis-
ease at any time during initial therapy or within 2 months after
completion of tre a t m e n t .
Statistical methods
Descriptive measures on continuous data were summa-
rized as medians and ranges. Survival analyses were per-
f o rmed using the product-limit method of Kaplan and
M e i e r, with 95% confidence intervals calculated using the
method of logit limits.
RESULTS
E n g r a f t m e n t
Stem cell sources included bone marrow plus PBSC in
eight patients (40%) and PBSC alone in 12 patients (60%).
T h ree patients received unmobilized PBSCs and 17
received mobilized PBSCs either with G-CSF alone (13) or
G-CSF plus chemotherapy (4). The median nucleated cell
number infused was 3.5831 08/kg (range 1.45–4.8). All
patients achieved complete hematopoietic re c o v e ry. The
median number of days to reach an absolute granulocyte
count of .0 . 531 09/L was 11 days (range 9–22), and the
median number of days to a self-sustaining platelet count of
20 3 109/L was 12 days (range 10–182).
Tox i c i t y
T h e re was no transplant-related mort a l i t y. The major
nonhematological toxicities of the preparative re g i m e n s
consisted primarily of oral and GI mucositis and skin
inflammation related to high-dose etoposide and TBI. One
patient developed congestive cardiomyopathy while in
remission at 4 years after ASCT and has improved on med-
ical therapy. Thus far, no patient has developed myelodys-
plasia or acute leukemia.
S u rv i v a l
All 20 patients are alive and in complete remission at a
median follow-up of 42.8 months (range, 13.2–149.2) and
their Kaplan-Meier survival curve is shown in Fig. 1. None
of the patients has relapsed.
DISCUSSION
Only a few studies have re p o rted the use of HDT and
ASCT as consolidative therapy during first CR for patients
with poor- p rognosis HD. Carella et al. re p o rted their pilot
study in 1991 [12] and recently updated the long-term follow-
up results in 22 poor-risk HD patients who received trans-
plants in first CR after MOPP/ABVD chemotherapy [20].
The high-dose regimens consisted of cyclophosphamide,
etoposide, and carmustine (CBV) in 18 patients and carm u s-
tine, etoposide, cytosine arabinoside, and melphalan in 4
patients. Eighteen of 22 patients were alive and 17 (77%)
remained in continuous remission at a median follow-up of
86 months (range 34–114). There was only one tre a t m e n t -
related death attributable to interstitial pneumonitis. In the
re t rospective study re p o rted by Sureda et al. f rom the Spanish
Cooperative Group GEL-TAMO [15], 27 HD patients
u n d e rwent ABMT during first CR, including five patients
who re q u i red second-line therapy to achieve CR. The poor
p rognostic factors were identified re t rospectively and includ-
ed stage IV, bulky mediastinal disease, extranodal involve-
ment, and bone marrow involvement. Six patients had four of
these poor risk factors, 12 had three factors, and six had two
factors. With a median follow-up of 30 months (range 8–66),
21 patients (78%) were alive and in continuous re m i s s i o n .
In an attempt to evaluate the survival benefit of early
HDT and ASCT during first CR, a case-matching study
was conducted by the European group for Blood and
M a rrow Transplantation (EBMT) and the German Hodgkin’s
Lymphoma Study Group (GHSG) [16]. In this study, the
outcome of 56 patients who received early HDT and ASCT
while in first CR identified via the EBMT lymphoma reg-
istry were compared to 168 patients with similar prognostic
f e a t u res at diagnosis who achieved CR after conventional
chemotherapy with or without radiotherapy in the GHSG
trials. Patients were matched based on a preceding pro g n o stic
factor analysis of the GHSG. The relapse-free survival was
significantly longer in the ASCT group; however, there was
no significant diff e rence in overall survival (OS). These
results showed that early HDT and ASCT during first CR
may improve failure - f ree survival, but OS advantages have
not yet been demonstrated due to effective salvage therapy
including ASCT at the time of relapse.
The general prognosis of patients who fail to achieve
initial complete remission after conventional chemotherapy
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is poor, but it is very important to make a distinction
between patients with primary re f r a c t o ry disease, induction
f a i l u re, or first PR. Patients with minimal residual disease
after primary therapy (first PR) may be classified as induc-
tion failure, but their prognoses are diff e rent from those
with pro g ressive disease on therapy. Excellent results have
been re p o rted when ASCT was perf o rmed during first PR
in advanced-stage HD patients [14,17]. The French re g-
i s t ry analyzed the outcome of HDT and ASCT in 158
patients with advanced HD, including 85 in first PR, 45 in
first CR, and 28 with primary re f r a c t o ry disease [17]. The
cumulative probabilies of 5-year OS and DFS were 83%
and 76%, re s p e c t i v e l y, for the first PR, and 76% and 70%,
re s p e c t i v e l y, for the first CR group. There was no diff e r-
ence in the DFS or OS between the first CR and first PR
g roup. Similar results were re p o rted by Fleury et al. [14] in
23 patients with poor prognosis stage IV HD who were
transplanted while in first CR (13) or first PR (10). These
results suggest that HDT and ASCT should be off e red to
advanced-stage HD patients who achieve only part i a l
remission after initial induction chemotherapy.
Our pre l i m i n a ry results also show that HDT therapy
and ASCT during first PR/CR may prevent relapse and
i m p rove long-term disease-free survival in selected patients
with advanced-stage poor-risk HD. These results support
the experiences re p o rted previously by the Italian, Fre n c h ,
and Spanish study teams. Early HDT and ASCT appears to
be the best option for patients in first PR, yet the role of
this therapy in high-risk first CR patients remains uncer-
tain. Despite the excellent outcome re p o rted following
HDT and ASCT in first CR, these results are pre l i m i n a ry
and must be interpreted with caution because of the small
number of highly selected patients, a nonrandomized
design, and the lack of uniform poor prognostic factors uti-
lized in these studies. Further studies are re q u i red to con-
f i rm the survival benefit of early HDT and ASCT during
first CR in poor-risk HD patients. In addition, the question
re g a rding the optimal timing of ASCT in poor-risk HD
remains unanswered. Since HDT and ASCT is an eff e c t i v e
salvage therapy for patients with relapsed HD [19], should
this pro c e d u re be re s e rved for high-risk patients only at the
time of relapse, thus avoiding the unnecessary risk and toxi-
city to those who may already have been cured with con-
ventional therapy? These questions can only be answered in
p rospective randomized studies comparing early HDT and
ASCT in first CR with conventional chemotherapy and
ASCT at relapse in advanced-stage HD patients with uni-
f o rm poor risk factors.
Unlike non-Hodgkin’s lymphoma (NHL), poor pro g-
nostic features for patients with advanced-stage HD have
not been well established or uniformly accepted, and the
high-risk group has not been clearly identified. Several
p rognostic models have been proposed and re p o rt e d
[4–7,21], however, these models were developed based on
the data from moderate sample size, the prognostic factors
w e re not the same in each model, and not all the variables
had a significant effect when applied to patients in other
studies [7]. For example, the Memorial Sloan-Kettering
Cancer Center model was constructed based on six inde-
pendent unfavorable prognostic factors, including low
hematocrit, high serum LDH, age .45 years, inguinal
node involvement, mediastinal mass .0.45 of the thoracic
d i a m e t e r, and bone marrow involvement [4]. The Christie
Hospital, Manchester, UK, and St. Bart h o l o m e w ’s Hospi-
tal, London, UK, model was based on age, sex, lymphocyte
count, and stage [5]; and the Scotland and Newcastle Ly m-
Figure 1. Kaplan-Meier estimate of probability of overall and disease-free survival for the 20 patients with poor-risk Hodgkin’s disease who received transplants
during first CR or PR.
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phoma Group, Edinburgh, UK, numeric prognostic index
was based on four variables: age, stage, absolute lympho-
cyte count, and hemoglobin [6]. In addition, when these
models were applied to 344 patients with advanced-stage
HD treated according to the H89 protocol in the Gro u p
d’Etudes des lymphomes de l’Adulte study, none of these
models was successful in identifying a high-risk gro u p
based on survival rate [7].
Recently, an international effort was organized and data
w e re collected from 25 centers and study groups on 5141
patients treated with combination chemotherapy with or
without radiotherapy for advanced-stage HD [22]. Seven
poor prognostic factors were identified, each of which
reduces tumor control by 7% to 8% at 5 years. These fac-
tors included age $45 years, male sex, stage IV, serum albu-
min ,4 gm/dL, hemoglobin ,10.5 gm/dL, white blood cell
count $1 5 , 0 0 0 /mL, and a lymphocyte count ,6 0 0 /mL .
Patients with $ five factors had a 5-year freedom from pro-
g ression rate of 42%. When we apply these intern a t i o n a l
p rognostic factors to patients in this study, 13 of the 20
patients (65%) had three or more risk factors, although the
data were incomplete in 5 patients (Table 2.). Thus, this
p rognostic score may be useful in identifying high-risk
patients who may be candidates for more intensive tre a t-
ment such as HDT and ASCT during first CR.
The use of consolidative radiation therapy to chemo-
therapy has been shown to reduce local relapse and impro v e
d i s e a s e - f ree survival in HD patients with locally extensive,
bulky mediastinal disease [23], however, the use of adjuvant
radiation therapy to chemotherapy in HD patients with
advanced-stage III and IV has not been well established,
especially in those with bulky disease above and below the
diaphragm. Since radiation therapy remains a vital compo-
nent in the treatment of HD, especially for providing local
c o n t rol, we have utilized TBI in our high-dose regimen. So
f a r, our results are encouraging, with no relapse occurring at
the previous sites of bulky disease and no re g i m e n - re l a t e d
m o rt a l i t y. A diff e rent approach was used in the study re p o rte d
by Fleury et al., in which mediastinal radiotherapy (26 Gy)
was delivered before high-dose chemotherapy (CBV re g i-
men), and total lymphoid irradiation (20 Gy) was delivere d
posttransplant [14]. Thus, the role of radiation therapy in the
high-dose therapy setting remains unanswered, and furt h e r
studies are re q u i red, specifically to determine how to deliver
radiation therapy effectively without additional toxicity. In
addition, long-term follow-up will be necessary to evaluate
the incidence of second malignancies, especially solid
tumors, myelodysplasia, and card i o p u l m o n a ry complications
associated with the combined use of involved-field radiothera p y
with TBI or high-dose chemotherapy re g i m e n s .
Dose-intensive combination chemotherapy re g i m e n s
with or without growth-factor support have also been investi-
gated in advanced-stage HD patients with encouraging
results [10,11]. The GHSG conducted a phase II study with
the intensified bleomycin, etoposide, doxorubicin, cyclophos-
phamide, vincristine, prednisone, and procarbazine (BEA-
COPP) regimen plus growth-factor support in 60 patients
with advanced-stage HD [11]. Radiotherapy was given after
chemotherapy to initial bulk lesions and residual disease.
N i n e t y - t h ree percent of patients achieved complete re m i s-
sion, and, at a median follow-up of 32 months, overall sur-
vival and freedom from treatment failure were estimated to
be 91% and 90%, re s p e c t i v e l y. The Stanford group designed
a seven-drug regimen (Stanford V), completed in 12 weeks
followed by radiotherapy (36 Gy) in patients with initial bulky
disease (.5 cm) or macroscopic splenic disease [10]. Sixty-fiv e
p reviously untreated stage II patients with bulky mediastinal
involvement and stage III and IV HD patients were tre a t e d .
The 3-year failure - f ree survival rate for advanced-stage III
and IV patients combined was 82%, however, it should be
noted that most patients in both studies did not have poor-
p rognostic disease based on the International Pro g n o s t i c
S t u d y. There f o re, further studies of these two re g i m e n s
should be conducted in poor-risk advanced HD patients in a d d i-
tion to current ongoing phase III randomized trials [ 2 4 , 2 5 ] .
Tr a n s p l a n t - related toxicity is the major concern following
HDT and ASCT during first CR. One patient in our study
developed congestive cardiomyopathy at 4-years posttrans-
plant, a complication that has been well described in
patients who receive ABVD alone or as combined modality
therapy [2]. Therapy-induced myelodysplastic syndro m e
( M D S ) / s e c o n d a ry acute leukemia and second malignancies
are also major concerns, since these complications have been
reported in patients with HD [17] and NHL [26] following
ABMT during first remission. Longer follow-up will be
re q u i red to assess long-term toxicity including decre a s e d
fertility, gonadal dysfunction, and cardiopulmonary compli-
cations as well as the risk and incidence of secondary malig-
nancies associated with high-dose therapy regimens.
In conclusion, the results from our study suggest a
potential role of HDT and ASCT during first CR/PR for
patients with unfavorable prognosis and advanced-stage
HD. The procedure is safe and is associated with low treat-
m e n t - related mort a l i t y, however, this treatment appro a c h
remains investigational, and randomized studies comparing
HDT and ASCT with conventional chemotherapy in
patients with unfavorable prognostic features and advanced-
stage Hodgki n ’s disease should be conducted. Pro g n o s t i c
factors and risk groups recently described by the intern a-
tional collaborative group may be useful in identifying high-
risk patients who are candidates for more intensive therapy,
such as high-dose therapy and stem cell transplantation.
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